In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Call For Action: Pharma Strategies For Development Of Payor Evidence Programs

Executive Summary

The biopharma industry invests substantially in post-approval studies to convey information about the value of its products to constituents, but the majority of these efforts do not address core, real-world questions raised by payors. A new business model recognizing the strategic value of medical affairs to market access is needed to stem the tide of disappointing reimbursement decisions.

You may also be interested in...



Getting Results From Big Data Depends On Trust Between Stakeholders

Manufacturers, payers and providers will need to learn how to trust each other’s data sources if the benefits of the big datasets of real-world evidence are to be realized, pharmaceutical execs say.

Big Data Transforming The Role Of Pharma, IBM Analytics Partner Says

Pharmaceutical companies are beginning to leverage big data to become more integrated into health care delivery, looking to care coordination and other “services adjacent to medicines,” IBM’s John Piccone reports.

Projecting Market Access Success For Early-Stage Pharma Assets: Getting Past The Hurdles

All too often, pharmaceutical companies and investors put up hurdles, but they can and must identify indications and assets with high future market access potential in early stages by adjusting the early screening and evaluation process.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel